Chen DLT, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins A, Chisholm D, Samocha-Bonet D, Macefield VG, Greenfield JR. 

**Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men.**

*Frontiers in Physiology 2017, 8: 101.*

Copyright:

© 2017 Chen, Brown, Liess, Poljak, Xu, Zhang, Trenell, Jenkins, Chisholm, Samocha-Bonet, Macefield and Greenfield. This is an open-access article distributed under the terms of the [Creative Commons Attribution License (CC BY)](https://creativecommons.org/licenses/by/4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

DOI link to article:

[https://doi.org/10.3389/fphys.2017.00101](https://doi.org/10.3389/fphys.2017.00101)

Date deposited:

08/05/2017

This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0)
Muscle Sympathetic Nerve Activity Is Associated with Liver Insulin Sensitivity in Obese Non-Diabetic Men

Daniel L. T. Chen¹, Rachael Brown²,³, Carsten Liess⁴, Anne Poljak⁵,⁶, Aimin Xu⁷, Jialiang Zhang⁷, Michael Trenell⁸, Arthur Jenkins¹,⁹, Donald Chisholm¹, Dorit Samocha-Bonet¹,⁶, Vaughan G. Macefield²,³ and Jerry R. Greenfield¹,¹⁰

¹Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, NSW, Australia, ²School of Medicine, University of Western Sydney, Sydney, NSW, Australia, ³Neuroscience Research Australia, Sydney, NSW, Australia, ⁴Philips Healthcare, Luebeckertordamm, Hamburg, Germany, ⁵Bioanalytical Mass Spectrometry Facility, UNSW Sydney, Sydney, NSW, Australia, ⁶School of Medical Sciences, UNSW Sydney, Sydney, NSW, Australia, ⁷State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, Hong Kong, ⁸Movellab, Newcastle University, Newcastle, UK, ⁹School of Health Science, University of Wollongong, Wollongong, NSW, Australia, ¹⁰Department of Endocrinology and Diabetes Center, St. Vincent’s Hospital, Sydney, NSW, Australia

Introduction: Muscle sympathetic nerve activity (MSNA) may play a role in insulin resistance in obesity. However, the direction and nature of the relationship between MSNA and insulin resistance in obesity remain unclear. We hypothesized that resting MSNA would correlate inversely with both muscle and liver insulin sensitivity and that it would be higher in insulin-resistant vs. insulin-sensitive subjects.

Materials and methods: Forty-five non-diabetic obese subjects were studied. As no significant relationships were found in women, the data presented in on 22 men aged 48 ± 12 years. Two-step (15 and 80 mU/m²/ min) hyperinsulinaemic-euglycaemic clamps were performed using deuterated glucose to determine liver and muscle insulin sensitivity. Clinical and metabolic parameters were assessed. MSNA was measured via a microelectrode inserted percutaneously into the common peroneal nerve.

Results: MSNA burst frequency correlated inversely with liver insulin sensitivity ($r = -0.53, P = 0.02$) and positively with the hepatokines C-reactive protein (CRP) and fibroblast growth factor (FGF)-19 ($r = 0.57, P = 0.006$, and $r = -0.47, P = 0.03$, respectively). MSNA burst frequency was lower in Liver$_{sen}$ compared to Liver$_{res}$ (27 ± 5 vs. 38 ± 2 bursts per minute; $P = 0.03$). Muscle insulin sensitivity was unrelated to MSNA.

Discussion: Sympathetic neural activation is related to liver insulin sensitivity and circulating hepatokines CRP and FGF-19 in non-diabetic obese men. These results suggest a potential hepato-endocrine-autonomic axis. Future studies are needed to clarify the influence of MSNA on liver insulin sensitivity in men.

Keywords: obesity, insulin resistance, muscle sympathetic nervous activity, men, liver insulin sensitivity
INTRODUCTION

The sympathetic nervous system (SNS) plays an important role in homeostasis and metabolism, influencing resting metabolic rate, energy expenditure, and glucose and lipid metabolism (Astrup et al., 1995; Stob et al., 2007). Resting muscle sympathetic nerve activity (MSNA) regulates vasoconstriction, and is a major determinant in the control of blood pressure. MSNA has been shown to be higher in normotensive obese vs. lean individuals (Scherrer et al., 1994; Grassi et al., 1995). It has also been shown to decrease with weight loss (Straznicky et al., 2010).

Obesity is associated with insulin resistance and other metabolic complications, possibly contributed to by impaired sympathetic nerve activity. Hyperinsulinaemia is commonly observed in obesity; it is closely linked to peripheral and hepatic insulin resistance and has been shown to stimulate MSNA in humans (Landsberg, 1996; Greenfield and Campbell, 2008). Higher baseline MSNA and a blunted MSNA response to oral glucose is a characteristic of obese insulin-resistant individuals when defined by indirect oral glucose tolerance test (OGTT) indices (Straznicky et al., 2009). However, the nature and direction of the association between SNS activity and peripheral and hepatic insulin resistance remain unclear.

Muscle sympathetic nerve activity, measured directly using a microelectrode inserted percutaneously into a peripheral nerve (microneurography), is a reliable and reproducible assessment of sympathetic nerve activity (Grassi and Esler, 1999). Although MSNA accounts for only about 20% of whole body release of norepinephrine to plasma, it has been shown to be closely related to cerebral, cardiac, and renal noradrenaline spillover (Wallin et al., 1992, 1996; Lambert et al., 1997; Straznicky et al., 2008). There is a gender difference in MSNA among obese individuals (Brooks et al., 2015). MSNA has been shown to correlate with Body Mass Index (BMI), visceral adiposity, and waist circumference in obese men (Lambert et al., 2007), but not in premenopausal or postmenopausal women (Brooks et al., 2015). The reasons for this gender specificity are not completely understood, but it is proposed to relate to differences in adipose tissue disposition, inflammatory profiles, and pressor and depressor components of the renin aldosterone angiotensin system (Fischer et al., 2002; Brooks et al., 2015). Estrogen may play a role in resisting obesity-induced hypertension and MSNA elevation by suppressing inflammatory cytokines and reducing production and actions of pressor renin-aldosterone system components (Brooks et al., 2015), supported by differences observed in MSNA correlations between pre and postmenopausal women (Brooks et al., 2015).

We evaluated resting MSNA in 45 non-diabetic obese subjects who had undergone a two-step hyperinsulinaemic-euglycaemic clamp with deuterated glucose to assess liver and muscle insulin sensitivity (Chen et al., 2015). We hypothesized that resting MSNA would be correlated with both muscle and liver insulin sensitivity and that in subjects matched for adiposity, MSNA would be higher in liver and muscle insulin-resistant subjects compared to their insulin-sensitive counterparts.

MATERIALS AND METHODS

This is a subcomponent of a parent study that has been reported elsewhere (Chen et al., 2015). One hundred and eighty-four subjects aged 21–69 years were recruited from the general population by advertisements in local newspapers. The study was approved by St Vincent's Hospital Human Research Ethics Committee, Sydney. Subjects provided informed written consent prior to commencement of the study, which was conducted under the guidelines of the Declaration of Helsinki. Exclusion criteria were known renal, cardiac or liver disease, or active cancer and diabetes, >5% change in body weight in the preceding 3 months, medications that affect glucose metabolism (including diabetes medications, anti-psychotics and steroids) and >20 g of alcohol; based on these criteria 104 potential participants screened over the phone were excluded from the study.

The remaining 80 subjects underwent standard OGTT. Diabetes was defined according to the American Diabetes Association criteria (American Diabetes Association, 2014). Fourteen subjects were excluded due to difficult venous access or loss of interest. Of the 66 subjects remaining, all agreed to undergo MSNA studies; 45 (22 males) were successfully studied. Twenty one subjects (7 males) did not have successful MSNA recording due to technical issues or poor recording quality. As no relationships were found between MSNA indices and insulin resistance in females, data on males only are presented. No subject was treated with beta-blockers. Clamp studies were performed at the Clinical Research Facility at the Garvan Institute of Medical Research, Sydney as previously described (Milner et al., 2010). Recording of MSNA was performed at Neuroscience Research Australia (NeuRA), Sydney and magnetic resonance imaging (MRI) and dual-energy X-ray absorptiometry (DXA) at St Vincent's Hospital, Sydney.

Definition of Insulin Sensitivity in Muscle and Liver

All subjects underwent two-step (insulin infusion rates 15 and 80 mU/m²/min) hyperinsulinaemic-euglycaemic clamps with deuterated glucose (6,6-²H₂, Cambridge isotope, Andover) to assess muscle and liver insulin sensitivity as described previously (Milner et al., 2010; Petersons et al., 2013; Chen et al., 2015). The percentage of endogenous glucose production (EGP) suppression with low-dose insulin was used to define liver insulin sensitivity.

Liver insulin-sensitive men (Liver_{es}) were defined as the top tertile of EGP suppression and liver insulin-resistant men (Liver_{er}) as the bottom two tertiles, as previously described (Chen et al., 2015). The cut-off was based on an average prevalence of 30% insulin-sensitive obesity amongst the obese population in large cohort studies (Patakay et al., 2010).

Muscle insulin sensitivity was inferred from the glucose infusion rate (GIR) during the high-dose insulin clamp (GIR_{HI}) adjusted for fat-free mass (FFM). Study participants were assigned to the muscle insulin-sensitive (Muscle_{sen}) group if GIR_{HI} was in the top tertile of the cohort and to the muscle insulin-resistant (Muscle_{er}) group if in the bottom two tertiles. Our Muscle_{sen} group had comparable GIR_{HI} to that measured in a group of lean healthy individuals previously studied in
our Clinical Research Facility using a similar protocol (Tonks et al., 2013). As EGP was fully suppressed during the high-dose insulin infusion, GIR\textsubscript{HI} reflects peripheral (mainly muscle) insulin sensitivity.

**Anthropometry and Body Composition**

BMI was defined as weight in kilograms divided by height in meters squared. Waist circumference was measured as the widest circumference between the lower end of the ribs and the anterior superior iliac spines. Hip circumference was measured at the widest circumference between the greater trochanters and the anterior superior iliac spines. Total body fat mass, FFM and central abdominal fat were measured by DXA (Lunar Prodigy, GE-Lunar, Madison, WI, USA; S/ware 12.20). In some larger subjects, analysis was performed by aligning one side of the body on the scanner, and doubling the data to achieve overall body composition, as previously described (Chen et al., 2015).

**Magnetic Resonance Imaging**

MRI (3.0 T Philips Achieva, Philips Medical Systems, The Netherlands) images were acquired using the mDIXON technique to evaluate the amount of liver and subcutaneous fat. The amount of visceral adipose tissue was measured in five slices at the L4/L5 intervertebral disc level and quantified using Image J software 1.46r (NIH, USA). As described previously (Milner et al., 2010; Chen et al., 2015), visceral fat was calculated as the difference between total fat and subcutaneous fat. One subject was the weight limit of the MRI machine and so quantitative fat data were not available for this subject.

**Muscle Sympathetic Nerve Activity and Blood Pressure Measurement**

Measurements of resting MSNA were performed in a quiet room at 22°C in the seated position on a separate day to the clamp study. Subjects voided before commencement. MSNA was performed in a resting state with one-third of subjects studied in the afternoon due to attendance at the Garvan Institute in the morning. Subjects refrained from caffeine for 4 h prior to recording.

Subjects lay in a chair with their back at 45° angle and legs supported horizontally. Spontaneous resting MSNA was recorded by inserting an insulated tungsten microelectrode (Frederick Haer and Co., Bowdoinham, ME, USA) percutaneously at the level of the fibular head into the left common peroneal nerve and advanced toward a muscle fascicle of the nerve while delivering weak electrical impulses (0.01–1 mA, 0.2 ms, 1 Hz). An uninsulated reference electrode was inserted subdermally 2–3 cm from the recording electrode and a surface Ag–AgCl electrode applied to the leg served as the ground electrode. A muscle fascicle was defined as such if intraneural stimulation evoked muscle twitches of the ankle, toe dorsiflexors, or foot everter muscles with no radiating paraesthesia. Once a muscle fascicle had been entered, neural activity was amplified (band-pass 0.3–5 kHz, gain 2 × 10\textsuperscript{4}) using an isolated amplifier and headstage (NeuroAmpEx, AD Instruments, Sydney, Australia). The position of the electrode was then adjusted manually until spontaneous bursts of MSNA were identified. Once an acceptable nerve-recording site was obtained with both visual and acoustic identification of spontaneous sympathetic bursts, resting measurements were recorded and stored on computer (10 kHz sampling) using a computer based data acquisition and analysis system (PowerLab 16SP hardware and LabChart 7 software; AD Instruments).

Continuous non-invasive blood pressure was recorded using radial artery tonometry (CBM-7000, Colin Corp., Japan). The ECG (0.3 Hz–1 kHz) was recorded with surface electrodes on the chest and sampled at 2 kHz and respiration (DC-100 Hz).

MSNA burst amplitudes were measured from the RMS-processed signal (200 ms moving average) using the Peak Parameters feature of LabChart 7 (AD Instruments, Sydney, Australia). The entire process has been described previously (Macefield, 2013). MSNA was manually analyzed and expressed as burst frequency (bursts per minute) and burst incidence (bursts per 100 heart beats), averaged over 15 min. There were no significant differences in MSNA-measured variables between subjects in whom MSNA was recorded in the morning or the afternoon (morning n = 15; afternoon n = 7; independent t-test; P > 0.47).

**Laboratory Analyses**

Whole blood glucose was measured using the YSI 2300 STAT analyzer (Yellow Springs Ohio). Serum insulin and C-peptide concentrations were measured by radioimmunoassay (Millipore, St Charles, USA). Plasma lipid profiles were determined by an automated analyzer (Roche, IN, USA). Serum non-esterified fatty acids (NEFA) were analyzed by an enzymatic colorimetric assay (Wako, Osaka, Japan). Serum high sensitivity C-reactive protein (hsCRP), fibroblast growth factors FGF-19 and FGF-21, total adiponectin, fatty acid-binding protein 4 (FABP4), lipocalin 2 and retinol-binding protein 4 (RBP4) were analyzed by ELISA (Antibody and Immunoassay Services at the University of Hong Kong; Chen et al., 2015). The intra- and inter-assay CVs have been reported previously (Chen et al., 2015).

**Statistical Analysis**

Data were expressed as means ± SEM unless otherwise specified. Non-normally distributed data (serum triglycerides, insulin, NEFA, hsCRP, FGF-19, and FGF-21) were transformed logarithmically prior to statistical analysis. Student’s t-test was used to evaluate significant differences between the different phenotypes. Correlations were performed using Pearson’s correlation analysis. Chi-square and Fisher’s exact test were used to detect differences in timing of MSNA measurement in Liver\textsubscript{en} and Liver\textsubscript{res} groups. P < 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS version 21 (Chicago, IL, USA).

**RESULTS**

Baseline characteristics are presented in Table 1. Mean age was 48 ± 2 years and BMI was 34.7 ± 0.7 kg/m\textsuperscript{2} (range 30.9–46.7 kg/m\textsuperscript{2}). Mean systolic and diastolic blood pressure were 127 ± 14 and 83 ± 11 mmHg, respectively. Mean MSNA-derived measures were 56 ± 17 bursts per minutes and 34 ± 11 burst
per 100 heart beats. Five male subjects reported taking anti-hypertensive medications. There were no significant differences in MSNA burst frequency ($P = 0.53$) and MSNA burst incidence ($P = 0.30$) between men taking and not taking anti-hypertensive medications. Furthermore, no significant differences in average HbA1c between men treated and men not treated with anti-hypertensive medications was found ($P = 0.86$).

**Linear Regression Analyses**

Liver insulin sensitivity (expressed as EGP suppression) correlated inversely with MSNA burst frequency ($r = −0.53$, $P = 0.02$; Figure 1), but the inverse relationship with MSNA burst incidence failed to reach statistical significance ($r = −0.36$, $P = 0.12$). Fasting insulin tended to correlate with MSNA burst frequency ($r = 0.42$, $P = 0.05$), while muscle insulin sensitivity was not related to either MSNA burst frequency ($P = 0.09$) or burst incidence ($P = 0.4$).

MSNA burst frequency and incidence correlated positively with hsCRP (Figure 2A and $r = 0.45$, $P = 0.04$, respectively). FGF-19 correlated (Figure 2B) and RBP4 tended to correlate inversely with MSNA frequency ($P = 0.05$, Figure 2C). Factors unrelated to MSNA-derived variables were FGF-21 (Figure 2D), FABP4 (Figure 2E), lipocalin 2 (Figure 2F), and total adiponectin ($P > 0.16$).

Age correlated positively with MSNA burst incidence ($r = 0.61$, $P = 0.002$), but the relationship to burst frequency failed to reach statistical significance ($r = 0.37$, $P = 0.09$). Systolic blood pressure, diastolic blood pressure, subcutaneous and liver fat, serum triglycerides and HbA1c were not related to either MSNA burst incidence or frequency ($P > 0.09$).

**Stratification by Liver Insulin Sensitivity**

Given the significant inverse correlation between MSNA and liver insulin sensitivity, we stratified the cohort according to liver insulin sensitivity. The cohort was stratified based on EGP suppression level to Liver$_{sen}$ and Liver$_{res}$ (top tertile vs. bottom two tertiles, 72% EGP suppression as cut-off value).

Liver$_{sen}$ men had lower HbA1c (5.2 ± 0.1 vs. 5.6 ± 0.1%, $P = 0.01$), fasting insulin (14 [11–22] vs. 25 [17–41] mU/L, $P = 0.03$) and hsCRP (1.7 [1.0–2.1] vs. 4.3 [2.2–5.7] mg/L, $P = 0.03$) than Liver$_{res}$ men, but had similar age (Liver$_{sen}$ = 0.14), BMI (Liver$_{sen}$ = 0.79), central abdominal fat (Liver$_{sen}$ = 0.58), and systolic (Liver$_{sen}$ = 0.10) and diastolic (Liver$_{sen}$ = 0.66) blood pressure. MSNA burst frequency was significantly lower in Liver$_{sen}$ men compared with Liver$_{res}$ men (27 ± 5 vs. 38 ± 2; $P = 0.03$, Figure 3). MSNA burst incidence tended to be lower in Liver$_{sen}$ men (Figure 3, $P = 0.06$).

**DISCUSSION**

To our knowledge, this is the first study to directly assess liver insulin sensitivity and MSNA in obese non-diabetic subjects. Basal SNS activity measured by MSNA was closely associated

---

**TABLE 1 | Clinical characteristics.**

| Characteristics | Value |
|-----------------|-------|
| Age (years)     | 48 ± 12 |
| BMI (kg/m$^2$)  | 34.7 ± 3.3 |
| Waist circumference (cm) | 114 ± 9 |
| Whole body fat (kg) | 40 ± 7 |
| Fat-free mass (kg) | 64 ± 6 |
| Central abdominal fat (kg) | 3.7 ± 0.6 |
| Subcutaneous fat (cm$^2$) | 441 ± 117 |
| Liver fat (%) | 16 ± 15 |
| SBP (mmHg)      | 127 ± 14 |
| DBP (mmHg)      | 83 ± 11 |
| Burst incidence | 56 ± 17 |
| Burst frequency | 34 ± 11 |
| Heart rate (BPM) | 66 ± 7 |
| Total cholesterol (mmol/L) | 5.0 ± 0.9 |
| LDL cholesterol (mmol/L) | 3.3 ± 0.8 |
| HDL cholesterol (mmol/L) | 1.1 ± 0.2 |
| Triglycerides (mmol/L) | 1.1 (0.8–1.5) |
| NEFA (mmol/L) | 0.27 (0.25–0.32) |
| HbA1c (%) | 5.5 ± 0.3 |
| Fasting glucose (mmol/L) | 4.8 ± 0.4 |
| Fasting insulin (mU/L) | 18 (12–26) |
| hsCRP (mg/L) | 2.2 (1.4–4.9) |
| FGF 19 (ng/L) | 97 (56–152) |
| FGF 21 (ng/L) | 49 (16–159) |
| FabP 4 (µg/L) | 42 ± 17 |
| Lipocalin 2 (µg/L) | 44 ± 14 |
| RBP 4 (µg/L) | 12 ± 2 |
| Total adiponectin (mg/L) | 10 ± 4 |

Data are means ± SD.

**DISCUSSION**

To our knowledge, this is the first study to directly assess liver insulin sensitivity and MSNA in obese non-diabetic subjects. Basal SNS activity measured by MSNA was closely associated
with liver insulin sensitivity in men with obesity. The metabolic profile of the insulin-sensitive men with obesity in the present study was consistent with previous reports, including lower glycaemia, fasting insulin, and CRP (Samocha-Bonet et al., 2012). The present study highlights the importance of the cytokines CRP and FGF-19 in their correlations with MSNA in obese men. These findings suggest involvement of a potential hepato-endocrine-sympathetic axis.

We have shown that MSNA was lower in liver insulin-sensitive obese men. Previous studies that used hyperinsulinaemic-euglycaemic clamps and microneurography (Straznicky et al., 2012; Curry et al., 2014) did not report any gender specific differences in the relationship between MSNA and whole body insulin sensitivity. Nevertheless, these studies included younger (18–35 years) non-obese (BMI <28 kg/m²) individuals (Curry et al., 2014) or pre-diabetic and diabetic individuals (Straznicky et al., 2012), making comparisons with our study difficult. MSNA has been shown to be regulated differently in men and women (Scherrer et al., 1994; Lambert et al., 2007).

Previous studies have reported that resting MSNA was higher in obese insulin-resistant subjects compared to their insulin-sensitive counterparts when defined by OGTT (Straznicky et al., 2009). The OGTT-derived Matsuda and Defronzo index of insulin sensitivity measures a composite of hepatic and muscle insulin action (Matsuda and DeFronzo, 1999) and our findings refine these and suggest that the relationship between insulin sensitivity and resting MSNA reported previously is predominantly contributed by the liver.

Serum FGF-19 correlated inversely with resting MSNA and was higher in insulin-sensitive compared with insulin-resistant men. FGF-19 has been shown to coordinate bile acid and glucose metabolism (Kharitonenkov et al., 2005). Liver is the main target organ of FGF-19 action, where FGF-19 binds to the FGFR 4/β-klotho complex to reduce gluconeogenesis and triglycerides in...
FIGURE 3 | Heart rate, burst incidence and burst frequency measured by MSNA in obese men stratified by liver insulin sensitivity. Differences between groups were analyzed by Student T-test, *P < 0.05.

the liver (Cicione et al., 2012). FGF-19 functions in a coordinated temporal fashion with insulin to inhibit gluconeogenesis and promote glycogen synthesis after a meal (Cicione et al., 2012). FGF-19 and insulin may exert differential actions when they are involved with the SNS, as FGF-19 correlated inversely with MSNA, compared with a positive correlation between fasting insulin and MSNA. We also demonstrated a positive correlation between hsCRP and resting MSNA. While these associations cannot determine cause and effect, they may suggest the existence of a hepato-endocrine-autonomic axis, where liver-related cytokines play a role in regulating sympathetic nerve activity or vice versa. Further, clamp studies using deuterated glucose tracers to measure hepatic insulin sensitivity and noradrenaline spillover to measure sympathetic nerve activity on larger cohorts are needed to clarify the nature of the associations between hepatic insulin sensitivity, cytokines and sympathetic nerve activity.

LIMITATIONS

Our study has some limitations. First, MSNA was not uniformly measured at the same time of the day. Nevertheless, MSNA measurements (MSNA burst frequency/incidence) performed at different times (morning versus afternoon) were not different. There were also no significant differences between the proportions of men in the higher MSNA measurement group (stratified by top tertile of MSNA burst incidence/frequency) performed in the morning or afternoon (chi-square p > 0.64). This finding has been supported by previous studies where MSNA, measured in the non-fasting state, did not differ between the morning and afternoon (Middlekauff and Sontz, 1995; Hissen et al., 2015). Second, MSNA measured in the peroneal nerve does not directly assess hepatic sympathetic nerve activity. Third, we recognize that this is an observational study that cannot infer causality. Finally, dissociation between regional and systemic sympathetic nerve activity has been described previously and regional noradrenaline spillover measurement may have more precisely assessed regional sympathetic nerve activity (Grassi and Esler, 1999).

In summary, basal sympathetic outflow to the muscle vascular bed is lower in insulin-sensitive compared to insulin-resistant men. Resting MSNA is inversely related to liver insulin sensitivity and may be mediated by liver-related factors in non-diabetic obese men. Further studies are needed to examine this putative hepato-endocrine-autonomic axis.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of St Vincent’s Hospital Human Research Ethics Committee, Sydney. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the St Vincent’s Hospital Human Research Ethics Committee, Sydney.

AUTHOR CONTRIBUTIONS

DLC, RB, DC, DS-B, VM, and JG designed the studies. DLC and RB performed the clinical studies. DLC, RB, DS-B, AP, AX, and JZ performed laboratory analysis of the data collected. DLC, MT, and CL performed and assisted in measuring visceral and subcutaneous adipose tissue. DLC, RB, DC, DS-B, VM, AJ, and JG interpreted the data. DLC wrote the manuscript. All authors edited and approved the final version of the manuscript. JG, VM, and DS-B are the guarantors of this work, have full access to all the data, and take full responsibility for the integrity and the accuracy of data analysis.

FUNDING

The study was funded by the National Health and Medical Research Council (NHMRC) and in part, by St. Vincent’s Clinic Foundation, Australia. DLC is funded by an Australian Postgraduate Awards (APA) Scholarship. JG is the recipient of the Don Chisholm Fellowship (funds from Garvan Research Foundation, including support from GlaxoSmithKline, Australia, Diabetes Australia Research Trust, the Commonwealth Department of Health and Ageing). No funding bodies had any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

ACKNOWLEDGMENTS

We thank the study nurses R. Richens, L. Schofield, J. Evans and V. Travers (Clinical Research Facility, Garvan Institute of Medical Research, Sydney) for their assistance in performing these studies.
REFERENCES

American Diabetes Association (2014). Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl. 1), S14–S80. doi: 10.2337/dc14-S014

Astrup, A., Buemann, B., Glud, C., Bennett, P., Tjur, T., and Christensen, N. (1995). Prognostic markers for diet-induced weight loss in obese women. Int. J. Obes. Relat. Metab. Disord. 19, 275–278.

Brooks, V. L., Shi, Z., Holwerda, S. W., and Fadel, P. J. (2015). Obesity-induced increases in sympathetic nerve activity: sex matters. Auton. Neurosci. 187, 18–26. doi: 10.1016/j.autneu.2014.11.006

Chen, D. L., Liess, C., Poljak, A., Xu, A., Zhang, J., Thoma, C., et al. (2015). Phenotypic Characterization of insulin-resistant and insulin-sensitive obesity. J. Clin. Endocrinol. Metab. 100, 4082–4091. doi: 10.1210/jc.2015-2712

Cicone, C., Degirolamo, C., and Moschetta, A. (2012). Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Gastroenterology 142, 4082–4091. doi: 10.1053/j.gastro.2012.02.036

Grassi, G., Eikels, N., Lambert, E. A., and Esler, M. D. (2008). Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 10, 440–447. doi: 10.1007/s11908-008-0083-1

Grassi, G., Seravalle, G., Cattaneo, B. M., Bolla, G. B., Lanfranchi, A., Colombo, M., et al. (1995). Sympathetic activation in obese normotensive subjects. Hypertension 25, 560–563. doi: 10.1161/01.HYP.25.4.560

Greenfield, J. R., and Campbell, L. V. (2008). Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: targets for therapy? Curr. Pharm. Des. 14, 1815–1820. doi: 10.2174/138161208784746716

Grassl, S., Hesse, M., Macefield, V. G., Brown, B., Witter, T., and Taylor, C. E. (2015). Baroreflex modulation of muscle sympathetic nerve activity at rest does not differ between morning and afternoon. Front. Neurosci. 9:312. doi: 10.3389/fnins.2015.00312

Kharitonenkova, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., et al. (2009). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635. doi: 10.1172/JCI32606

Lambert, E., Straznicky, N., Eikels, N., Esler, M., Dawood, T., Masuo, K., et al. (2007). Gender differences in sympathetic nerve activity: influence of body mass and blood pressure. J. Hypertens. 25, 1411–1419. doi: 10.1097/HJH.0b013e3281053af4

Lambert, G. W., Thompson, J. M., Turner, A. G., Cox, H. S., Wilkinson, D., Vaz, M., et al. (1997). Cerebral noradrenaline spillover and its relation to muscle sympathetic nerve activity in healthy human subjects. J. Auton. Nerv. Syst. 64, 57–64. doi: 10.1016/S0165-1838(97)00018-0

Landsberg, L. (1996). Obesity and the insulin resistance syndrome. Hypertens. Res. 19(Suppl. 1), S31–S55. doi: 10.1291/hypres.19.Supplement1_S31

Macefield, V. G. (2013). Sympathetic microcircueroaphy. Handb. Clin. Neurol. 117, 353–364. doi: 10.1016/B978-0-444-53491-0.00028-6

Matsuda, M., and DeFronzo, R. A. (1999). Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470. doi: 10.2337/diacare.22.9.1462

Middlekauff, H. R., and Sontz, E. M. (1995). Morning sympathetic nerve activity is not increased in humans. Implications for mechanisms underlying the circadian pattern of cardiac risk. Circulation 91, 2549–2555. doi: 10.1161/01.CIR.91.10.2549

Milner, K. L., van der Poorten, D., Trell, M., Jenkins, A. B., Xu, A., Snythe, G., et al. (2010). Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 139, 932–941. doi: 10.1053/j.gastro.2009.11.050

Pataky, Z., Bobbioni-Harsch, E., and Golay, A. (2010). Open questions about metabolically normal obesity. Int. J. Obes. (Lond.) 34(Suppl. 2), S18–S23. doi: 10.1038/ijo.2010.235

Petersen, C. J., Mangelsdorf, B. L., Jenkins, A. B., Poljak, A., Smith, M. D., Greenfield, J. R., et al. (2013). Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care 36, 2822–2829. doi: 10.2337/dc12-2617

Samocha-Bonet, D., Chisholm, D. J., Tonks, K., Campbell, L. V., and Greenfield, J. R. (2012). Insulin-sensitive obesity in humans - a ‘favorable fat’ phenotype? Trends Endocrinol. Metab. 23, 116–124. doi: 10.1016/j.tem.2011.12.005

Scherrer, U., Randin, D., Tappy, L., Vollenweider, P., Jequier, E., and Nicod, P. (1994). Body fat and sympathetic nerve activity in healthy subjects. Circulation 89, 2634–2640. doi: 10.1161/01.CIR.89.6.2634

Steh, N. R., Bell, C., van Baak, M. A., and Seals, D. R. (2007). Thermic effect of food and beta-adrenergic thermogenic responsiveness in habitually exercising and sedentary healthy adult humans. J. Appl. Physiol. 103, 616–622. doi: 10.1152/japplphysiol.1434.2006

Straznicky, N. E., Eikels, N., Lambert, E. A., and Esler, M. D. (2008). Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 10, 440–447. doi: 10.1007/s11908-008-0083-1

Stray-Pedersen, C. J., Mangelsdorf, B. L., Bennett, P., Tjur, T., and Christensen, N. (1992). Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J. Physiol. 453, 45–58. doi: 10.1113/jphysiol.1992.sp019217

Wallin, B. G., Thompson, J. M., Jennings, G. L., and Esler, M. D. (1996). Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J. Physiol. 491(Pt 3), 881–887. doi: 10.1113/jphysiol.1996.sp021265

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Chen, Brown, Liess, Poljak, Xu, Zhang, Trell, Jenkins, Chisholm, Samocha-Bonet, Macefield and Greenfield. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.